Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Operating Leases (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Operating Leases for 7 consecutive years, with $67.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 7.44% to $67.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $67.0 million, a 7.44% decrease, with the full-year FY2025 number at $67.0 million, down 7.44% from a year prior.
  • Operating Leases was $67.0 million for Q4 2025 at Kymera Therapeutics, down from $68.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $77.0 million in Q4 2023 to a low of $12.1 million in Q4 2022.
  • A 5-year average of $48.3 million and a median of $67.7 million in 2025 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: fell 8.15% in 2022, then soared 534.18% in 2023.
  • Kymera Therapeutics' Operating Leases stood at $13.2 million in 2021, then decreased by 8.15% to $12.1 million in 2022, then skyrocketed by 534.18% to $77.0 million in 2023, then dropped by 5.98% to $72.4 million in 2024, then dropped by 7.44% to $67.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Operating Leases are $67.0 million (Q4 2025), $68.4 million (Q3 2025), and $69.8 million (Q2 2025).